HSGX vs. INGN, CLGN, SMTI, COCH, MLSS, RBOT, LFWD, NTRB, ZJYL, and PRQR
Should you be buying Histogenics stock or one of its competitors? The main competitors of Histogenics include Inogen (INGN), CollPlant Biotechnologies (CLGN), Sanara MedTech (SMTI), Envoy Medical (COCH), Milestone Scientific (MLSS), Vicarious Surgical (RBOT), ReWalk Robotics (LFWD), Nutriband (NTRB), Jin Medical International (ZJYL), and ProQR Therapeutics (PRQR). These companies are all part of the "medical" sector.
Histogenics (NASDAQ:HSGX) and Inogen (NASDAQ:INGN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends, earnings, community ranking and media sentiment.
Inogen has a consensus price target of $7.00, indicating a potential downside of 19.72%. Given Inogen's higher possible upside, analysts plainly believe Inogen is more favorable than Histogenics.
Histogenics has a beta of 3.1, meaning that its share price is 210% more volatile than the S&P 500. Comparatively, Inogen has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500.
Histogenics has a net margin of 0.00% compared to Inogen's net margin of -30.07%. Histogenics' return on equity of -34.96% beat Inogen's return on equity.
Inogen received 27 more outperform votes than Histogenics when rated by MarketBeat users. However, 71.66% of users gave Histogenics an outperform vote while only 70.44% of users gave Inogen an outperform vote.
Histogenics has higher earnings, but lower revenue than Inogen. Histogenics is trading at a lower price-to-earnings ratio than Inogen, indicating that it is currently the more affordable of the two stocks.
In the previous week, Inogen had 3 more articles in the media than Histogenics. MarketBeat recorded 3 mentions for Inogen and 0 mentions for Histogenics. Inogen's average media sentiment score of 0.32 beat Histogenics' score of 0.00 indicating that Inogen is being referred to more favorably in the news media.
40.4% of Histogenics shares are held by institutional investors. Comparatively, 89.9% of Inogen shares are held by institutional investors. 19.7% of Histogenics shares are held by insiders. Comparatively, 1.0% of Inogen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Histogenics and Inogen tied by winning 8 of the 16 factors compared between the two stocks.
Get Histogenics News Delivered to You Automatically
Sign up to receive the latest news and ratings for HSGX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HSGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Histogenics Competitors List
Related Companies and Tools
